|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT03072290 |
|
Date of registration:
|
01/03/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Corticosteroid Injection in Carpal Tunnel Syndrome
|
|
Scientific title:
|
Comparison of Different Dose of Steroid Injection in Carpal Tunnel Syndrome |
|
Date of first enrolment:
|
February 18, 2017 |
|
Target sample size:
|
56 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03072290 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Taiwan
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Clinical diagnosis of CTS
- The diagnosis of CTS was confirmed by electrophysiological tests.
Exclusion Criteria:
- presence of thenar atrophy
- existence of disorders such as hypothyroidism, diabetes mellitus, chronic renal
failure, or rheumatoid arthritis; any accompanying orthopedic or neurologic disorders
that could mimic CTS such as cervical radiculopathy, polyneuropathy, proximal median
nerve entrapment, or thoracic outlet syndrome
- prior steroid injection into the affected carpal tunnel within 6 months or ever
received carpal tunnel surgery
- history of distal radius fracture
- pregnancy or lactation
- regular use of systemic NSAIDs ,corticosteroids or diuretics
- known allergy to corticosteroids and local anesthetics.
- impaired cognitive function
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Carpal Tunnel Syndrome
|
|
Intervention(s)
|
|
Drug: Triamcinolone Acetonide
|
|
Drug: lidocaine hydrochloride
|
|
Primary Outcome(s)
|
|
Change from Baseline in the scores on the Boston Carpal Tunnel Questionnaire (BQ).
[Time Frame: at 6, 12 weeks]
|
|
Secondary Outcome(s)
|
|
Change from Baseline in compound muscle action potential amplitude (CMAP)
[Time Frame: at 6, 12 weeks]
|
|
Change from Baseline in Median nerve distal motor latency
[Time Frame: at 6, 12 weeks]
|
|
Change from Baseline in sensory nerve conduction velocity
[Time Frame: at 6, 12 weeks]
|
|
Change from Baseline in self-reported pain intensity
[Time Frame: at 6, 12 weeks]
|
|
Secondary ID(s)
|
|
2016-07-006A
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|